Myokines: Novel therapeutic targets for diabetic nephropathy

Ming Yang; Shilu Luo; Jinfei Yang; Wei Chen; Liyu He; Di Liu; Li Zhao; Xi Wang

doi:10.3389/fendo.2022.1014581

Myokines: Novel therapeutic targets for diabetic nephropathy

Front Endocrinol (Lausanne). 2022 Oct 25:13:1014581. doi: 10.3389/fendo.2022.1014581. eCollection 2022.

Authors

Ming Yang^{1

2}, Shilu Luo², Jinfei Yang², Wei Chen², Liyu He², Di Liu², Li Zhao³, Xi Wang^{1

4}

Affiliations

¹ Department of Nutrition, Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China.
³ Department of Reproduction and Genetics, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
⁴ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Abstract

With the increasing incidence of diabetic nephropathy (DN), there is an urgent need to find effective DN preventive and therapeutic modalities. It is widely believed that effective exercise is good for health. However, the beneficial role of exercise in kidney disease, especially in DN, and the underlying molecular mechanisms have rarely been reported. Muscle is not only an important motor organ but also an important endocrine organ, secreting a group of proteins called "myokines" into the blood circulation. Circulating myokines then move to various target organs to play different biological roles. In this review, we summarize the currently known myokines and the progress in research relating them to DN and discuss its potential as a therapeutic target for DN.

Keywords: FGF21; diabetic nephropathy; irisin; muscle; myokines.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus*
Diabetic Nephropathies* / metabolism
Exercise / physiology
Humans